PURPOSE: To analyze, study and interpret the increased levels of tumor markers in breast cancer patients without recurrence or metastasis. PATIENTS AND METHODS: We studied a series of 400 patients with stage 1 breast cancer during a 3-year follow-up after primary treatment. Follow-up included frequent serum estimation of CEA, CA 15.3, CA 125, CA 27-29, TPA and TPS tumor markers. RESULTS: Of 358 patients being continuously disease-free, 18 (5%) cases showed false-positive levels of tumor markers, associated with benign conditions and not to cancer recurrence or metastasis. These conditions included ovarian cysts, thyroid disorders, hepatitis, renal stone and sarcoidosis. CONCLUSION: The value of increased tumor markers should be interpreted cautiously because it doesn't always imply disease recurrence. Tumor markers may increase in many benign conditions.
PURPOSE: To analyze, study and interpret the increased levels of tumor markers in breast cancerpatients without recurrence or metastasis. PATIENTS AND METHODS: We studied a series of 400 patients with stage 1 breast cancer during a 3-year follow-up after primary treatment. Follow-up included frequent serum estimation of CEA, CA 15.3, CA 125, CA 27-29, TPA and TPS tumor markers. RESULTS: Of 358 patients being continuously disease-free, 18 (5%) cases showed false-positive levels of tumor markers, associated with benign conditions and not to cancer recurrence or metastasis. These conditions included ovarian cysts, thyroid disorders, hepatitis, renal stone and sarcoidosis. CONCLUSION: The value of increased tumor markers should be interpreted cautiously because it doesn't always imply disease recurrence. Tumor markers may increase in many benign conditions.
Authors: Gary A Ulaner; Chris C Riedl; Maura N Dickler; Komal Jhaveri; Neeta Pandit-Taskar; Wolfgang Weber Journal: J Nucl Med Date: 2016-02 Impact factor: 10.057
Authors: Erika J Schneble; Lindsey J Graham; Matthew P Shupe; Frederick L Flynt; Kevin P Banks; Aaron D Kirkpatrick; Aviram Nissan; Leonard Henry; Alexander Stojadinovic; Nathan M Shumway; Itzhak Avital; George E Peoples; Robert F Setlik Journal: J Cancer Date: 2014-03-16 Impact factor: 4.207